摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-fluoro-14-methyl-14,14a-dihydro-6H-indolo[2',1':3,4]pyrazino[2,1-b]quinazolin-9(7H)-one

中文名称
——
中文别名
——
英文名称
2-fluoro-14-methyl-14,14a-dihydro-6H-indolo[2',1':3,4]pyrazino[2,1-b]quinazolin-9(7H)-one
英文别名
6-Fluoro-21-methyl-10,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2,4(9),5,7,15,17,19-heptaen-14-one;6-fluoro-21-methyl-10,13,21-triazapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2,4(9),5,7,15,17,19-heptaen-14-one
2-fluoro-14-methyl-14,14a-dihydro-6H-indolo[2',1':3,4]pyrazino[2,1-b]quinazolin-9(7H)-one化学式
CAS
——
化学式
C19H16FN3O
mdl
——
分子量
321.354
InChiKey
AUUYHYVVLLJPTI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    24
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    28.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    2-fluoro-14-methyl-14,14a-dihydro-6H-indolo[2',1':3,4]pyrazino[2,1-b]quinazolin-9(7H)-one劳森试剂 作用下, 以 甲苯 为溶剂, 反应 4.0h, 以37.8%的产率得到2-fluoro-14-methyl-14,14a-dihydro-6H-indolo[2',1':3,4]pyrazino[2,1-b]quinazolin-9(7H)-thione
    参考文献:
    名称:
    吲哚并六氢吡嗪并喹唑啉酮类抗肿瘤化合物及 其制备方法
    摘要:
    本发明涉及医药技术领域,具体涉及一类吲哚并六氢吡嗪并喹唑啉酮类抗肿瘤化合物及其制备方法。本发明的吲哚并六氢吡嗪并喹唑啉酮类化合物,其化学结构式如通式I或通式II所示,该类化合物是通过对吴茱萸碱进行了系统的骨架跃迁设计与合成得到一类吴茱萸碱新骨架化合物,是新发现的一类全新结构的拓扑异构酶I/微管蛋白双重抑制剂,具有明显抗肿瘤活性。本发明还提供了该类化合物在制备拓扑异构酶I/微管蛋白双重抑制剂和抗肿瘤药物中的应用。
    公开号:
    CN103992326B
  • 作为产物:
    描述:
    5-氟吲哚-2-甲酸 在 sodium tetrahydroborate 、 硫酸 、 sodium hydride 、 cobalt(II) chloride 、 三氯氧磷 作用下, 以 四氢呋喃甲醇乙醇N,N-二甲基甲酰胺甲苯 、 mineral oil 为溶剂, 反应 19.25h, 生成 2-fluoro-14-methyl-14,14a-dihydro-6H-indolo[2',1':3,4]pyrazino[2,1-b]quinazolin-9(7H)-one
    参考文献:
    名称:
    Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer
    摘要:
    Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping. Structure-activity relationship studies led to the discovery of compound 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line. Further antitumor mechanism studies indicated that compound 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest. The quaternary ammonium salt of compound 15j (compound 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity. Indolopyrazinoquinazolinone derivatives represent promising multitargeting antitumor leads for the development of novel antitumor agents.
    DOI:
    10.1021/acs.jmedchem.9b01626
点击查看最新优质反应信息

文献信息

  • 吲哚并六氢吡嗪并喹唑啉酮类抗肿瘤化合物及 其制备方法
    申请人:中国人民解放军第二军医大学
    公开号:CN103992326B
    公开(公告)日:2016-09-28
    本发明涉及医药技术领域,具体涉及一类吲哚并六氢吡嗪并喹唑啉酮类抗肿瘤化合物及其制备方法。本发明的吲哚并六氢吡嗪并喹唑啉酮类化合物,其化学结构式如通式I或通式II所示,该类化合物是通过对吴茱萸碱进行了系统的骨架跃迁设计与合成得到一类吴茱萸碱新骨架化合物,是新发现的一类全新结构的拓扑异构酶I/微管蛋白双重抑制剂,具有明显抗肿瘤活性。本发明还提供了该类化合物在制备拓扑异构酶I/微管蛋白双重抑制剂和抗肿瘤药物中的应用。
  • Scaffold Hopping of Natural Product Evodiamine: Discovery of a Novel Antitumor Scaffold with Excellent Potency against Colon Cancer
    作者:Lei Wang、Kun Fang、Junfei Cheng、Yu Li、Yahui Huang、Shuqiang Chen、Guoqiang Dong、Shanchao Wu、Chunquan Sheng
    DOI:10.1021/acs.jmedchem.9b01626
    日期:2020.1.23
    Inspired by the natural product evodiamine, a novel antitumor indolopyrazinoquinazolinone scaffold was designed by scaffold hopping. Structure-activity relationship studies led to the discovery of compound 15j, which shows low nanomolar inhibitory activity against the HCT116 cell line. Further antitumor mechanism studies indicated that compound 15j acted by the dual inhibition of topoisomerase 1 and tubulin and induced apoptosis with G2 cell-cycle arrest. The quaternary ammonium salt of compound 15j (compound 15js) exhibited excellent in vivo antitumor activity (TGI = 66.6%) in the HCT116 xenograft model with low toxicity. Indolopyrazinoquinazolinone derivatives represent promising multitargeting antitumor leads for the development of novel antitumor agents.
查看更多